Basic biotech models don’t often change quickly or significantly. Science certainly moves forward, backwards, and sideways, and ideas fall in and out of favor; the platform-to-product continuum gets traversed by entrepreneurs and VCs once every three or four years, for example. But the central dogma of discovery, VC-backing, pharma validation and exit has held relatively firm for two decades; the question has mostly remained about where in that model a company begins corporate life, and less about the model itself.
Only every now and then do these models get a jolt—call it biotech’s version of punctuated equilibrium. And Ikaria Inc.,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
